Reporting owner

Fairmount Healthcare Fund II L.P.

Reporting owner CIK 0001769651 · Director · 10% owner

View SEC filings ↗

These transactions appear in filings associated with this reporting owner. Jointly reported quantities and amounts are unallocated; they are not this owner's individual purchases or total holdings. Names and roles reflect the relevant filing, and a reporting owner may be a person or an organization.

Reset

Transaction timeline

Who reported an acquisition, and when the transaction occurred.

PurchaseStock awardGift receivedExercise / conversionConversionOther acquisition

3 dated transactions · 5 of 5 reporting owners shown. Select one owner to focus the chart.

View timeline as a table
Transaction dateCompany / securityReporting ownersAcquisition type
Dec 4, 2025CRESCENT BIOPHARMA, INC.Pre-Funded Warrant (Right to Buy)Harwin Peter Evan · Fairmount Healthcare Fund II L.P. · Fairmount Funds Management LLC · Kiselak TomasPurchase
Dec 4, 2025CRESCENT BIOPHARMA, INC.Ordinary SharesHarwin Peter Evan · Fairmount Healthcare Fund II L.P. · Fairmount Funds Management LLC · Kiselak TomasPurchase
Oct 23, 2025Viridian Therapeutics, Inc.\DECommon StockFairmount Healthcare Fund II L.P. · Fairmount Funds Management LLC · Fairmount Healthcare Fund II GP LLCPurchase

Only transactions on this page are shown. Date windows end on the latest transaction date in this sample. Joint filings may appear on more than one row. Sales are not included. Share-price charts use a separate data source.

Transactions in associated filings

Reported insider acquisitions, ordered by filing date, newest first. Currency is shown only when reported.
Filed / transactedCompanyReporting ownersType / securityQuantityPrice / reference valueDetails
Trade: CRESCENT BIOPHARMA, INC.CBIO · company listings
Harwin Peter EvanDirector · 10% owner
Fairmount Funds Management LLCDirector · 10% owner
Kiselak TomasDirector · 10% owner
Joint filing · amounts unallocated
PurchasePre-Funded Warrant (Right to Buy)Derivative security · Code P131,43413.409Value: 1,762,398.506Currency not specifiedView ↗
Trade: CRESCENT BIOPHARMA, INC.CBIO · company listings
Harwin Peter EvanDirector · 10% owner
Fairmount Funds Management LLCDirector · 10% owner
Kiselak TomasDirector · 10% owner
Joint filing · amounts unallocated
PurchaseOrdinary SharesNon-derivative security · Code P1,360,00013.41Value: 18,237,600Currency not specifiedView ↗
Trade: Viridian Therapeutics, Inc.\DEVRDN · company listings
Fairmount Funds Management LLCDirector · 10% owner
Joint filing · amounts unallocated
PurchaseCommon StockNon-derivative security · Code P454,54522Value: 9,999,990Currency not specifiedView ↗